Leukemia immunotherapy treatment could fight other cancers, Tel Aviv team finds
search

Leukemia immunotherapy treatment could fight other cancers, Tel Aviv team finds

Israeli researchers discover specific type of white blood cells that can be engineered to attack solid tumors, with fewer side effects than chemotherapy

Luke Tress is a video journalist and tech reporter for the Times of Israel

From left: Tel Aviv University researchers Dr. Yaron Carmi, Diana Rasuluniriana, Dr. Peleg Ride. (Courtesy/Tel Aviv University)
From left: Tel Aviv University researchers Dr. Yaron Carmi, Diana Rasuluniriana, Dr. Peleg Ride. (Courtesy/Tel Aviv University)

Israeli researchers have found that a treatment used for the blood cancer leukemia could be an effective way to treat other cancers.

While chemotherapy, which targets cells that grow or divide quickly, is the most commonly used cancer treatment, it does collateral damage to non-cancerous dividing cells.

Immunotherapy, on the other hand, is a kind of cancer treatment that helps the body’s own immune system fight off the cancer itself.

“Chemotherapy damages all fast-growing cells, including hair follicles and cells that line the gastrointestinal tract, and this attack on healthy cells causes serious side effects, which include hair loss, nausea, mood changes, pain, anemia, nerve and muscle problems, and kidney issues,” said Dr. Yaron Carmi, who headed the study by Tel Aviv University’s Sackler Faculty of Medicine.

“Immunotherapy, on the other hand, is a type of biological therapy that uses the body’s own immune system to seek out and destroy cancer cells. Engineered T cells have been proven very successful in treating blood cancer but attempts to use them to fight solid cancers have been disappointing. Our engineered cells have now shown efficacy in attacking solid tumors as well,” Carmi said in a statement.

The study found that a type of immunotherapy called chimeric antigen receptor (CAR) T cell therapy, previously used to target cancer cells in the blood, could also kill solid tumor cells that are coated in specific antibodies.

T cells are a type of white blood cell that are active and central in the body’s immune response. T cells play a part in the body’s adaptive immunity to harmful invading pathogens.

Illustrative: equipment that administers chemotherapy drugs at the North Carolina Cancer Hospital in Chapel Hill, North Carolina, May 25, 2017. (AP Photo/Gerry Broome)

CAR T cell therapy uses altered T cells to fight cancers. The cells are taken from the patient and CAR structures are added to their surface. The receptors allow the T cells to target antigens on the tumor cells and kill them.

The Tel Aviv lab discovered a type of T cell called CD4+ with a specific receptor, which they found could be modified to engineer new T cells that are more effective at targeting tumor cells.

The process leads to side effects, which can include severe inflammation produced by an overactive immune system, but the drawbacks are less severe than those associated with chemotherapy. The T cell therapy is also longer-lasting than chemotherapy, which only works while the drug is in the patient’s body.

“Our engineered cells have the potential to overcome barriers usually faced by CAR T cell therapy and have shown efficacy in solid tumors. This finding has the capability to change the way cancer is treated, demonstrating that the immune system can be utilized to identify and fight all types of cancer,” Carmi said.

“Our lab discovered a distinct subset of helper T cells, also known as CD4+ T cells, that express the high-affinity receptor for IgG [an antibody] and efficiently kill tumor cells coated with these antibodies,” Carmi said. “This method uses CAR T cell therapy and combines it with antibody specificity. Based on this discovery we were able to engineer novel T cells with enhanced tumor-killing activity and higher specificity, compared with other T cell-based therapies for cancer.

The researchers have so far tested their altered T cells on mice and plan to start a phase I clinical trial in the next three years.

The study was published in August in The Journal of Clinical Investigation.

Join us!
A message from the Editor of Times of Israel
David Horovitz

The Times of Israel covers one of the most complicated, and contentious, parts of the world. Determined to keep readers fully informed and enable them to form and flesh out their own opinions, The Times of Israel has gradually established itself as the leading source of independent and fair-minded journalism on Israel, the region and the Jewish world.

We've achieved this by investing ever-greater resources in our journalism while keeping all of the content on our site free.

Unlike many other news sites, we have not put up a paywall. But we would like to invite readers who can afford to do so, and for whom The Times of Israel has become important, to help support our journalism by joining The Times of Israel Community. Join now and for as little as $6 a month you can both help ensure our ongoing investment in quality journalism, and enjoy special status and benefits as a Times of Israel Community member.

Become a member of The Times of Israel Community
read more:
comments